You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Litigation Details for Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)

✉ Email this page to a colleague

« Back to Dashboard

Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)

Docket	⤷ Sign Up	Date Filed	2014-07-25
Court	District Court, D. Delaware	Date Terminated	2017-04-17
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	ASTRAZENECA AB; LANNETT COMPANY INC.
Patents	6,750,237; 7,220,767; 9,289,432
Attorneys	Danielle A. Duszczyszyn; Stefan M. Miller
Link to Docket	External link to docket

Small Molecule Drugs cited in Impax Laboratories Inc. v. Lannett Holdings Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for Impax Laboratories Inc. v. Lannett Holdings Inc. (D. Del. 2014)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
2016-10-11	140		1–16 of U.S. Patent No. 6,750,237 (the “’237 patent”) and claims 1–16 of U.S. Patent No. 7,220,767… Objections PX‐1 6/15/2004 Patent: U.S. Patent No. 6,750,237 B1, Issued to Dearn, et al. … the PX‐3 Patent: File History of U.S. Patent No. 6,750,237 … I. THE ASSERTED CLAIMS OF U.S. PATENT NOS. 6,750,237 AND 7,220,767 ARE NOT… Holdings, Inc. v. Astrazenca AB of U.S. Patent No. 6,750,237 to PX‐85 7/28/2015 Dearn et al.	External link to document
2017-04-19	175		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,750,237 B1; 7,220,767 B2. (…2014 17 April 2017 1:14-cv-00984 830 Patent None District Court, D. Delaware	External link to document
2014-07-25	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,750,237 B2; 7,220,767 B2. (…2014 17 April 2017 1:14-cv-00984 830 Patent None District Court, D. Delaware	External link to document
2015-11-30	60		of several terms in U.S. Patent Nos. 6;750,237 ("the '237 patent") and 7,220,767 ("…construction for disputed terms in U.S. Patent Nos. 6,750,237 and 7,220,767. Within five days the parties…quot;It is a bedrock principle of patent law that the claims of a patent define the invention fo which …that the patents claim intranasal formulations. More importantly, review of the patents as a whole… 6 patent, 1:31-36, 2:7-9). Third, Examples 1-8 of the patents are directed to intranasal	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.